var _paq = window._paq = window._paq || []; /* tracker methods like "setCustomDimension" should be called before "trackPageView" */ _paq.push(['trackPageView']); _paq.push(['enableLinkTracking']); (function() { var u="https://rwrregs.matomo.cloud/"; _paq.push(['setTrackerUrl', u+'matomo.php']); _paq.push(['setSiteId', '1']); var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.data-privacy-src='//cdn.matomo.cloud/rwrregs.matomo.cloud/matomo.js'; s.parentNode.insertBefore(g,s); })();

Real World Evidence (RWE) 101 – Are Non-Interventional Studies Regulated?

RWE 101 – Are Non-Interventional Studies Regulated?

Yes, non-interventional studies (NIS) are regulated. While the specific regulations and requirements may vary by country, there are generally guidelines and provisions in place to ensure the conduct and reporting of non-interventional studies meet certain standards.

Here are some key points related to the regulation of non-interventional studies:

Ethical Considerations: Non-interventional studies involving human participants must adhere to ethical principles and guidelines (i.e., Declaration of Helsinki) and be approved by an ethics committe (IRB/REC). These guidelines often cover aspects such as informed consent, confidentiality, privacy protection, and the rights and welfare of study participants.

Data Protection: Regulations related to data protection and privacy, such as the EU General Data Protection Regulation (GDPR), are applicable to non-interventional studies. Researchers must ensure that the collection, storage, and processing of personal data comply with these regulations.

Regulatory Oversight: Regulatory authorities may have oversight over non-interventional studies, particularly when the studies are the results of a regulatory commitment (e.g., PMRs and PASS). In the EU, for example, the EMA provides guidance on non-interventional post-authorisation safety studies (PASS) (GVP Module VIII).

Good Pharmacovigilance Practices (EU): Non-interventional studies focused on post-authorization safety assessments of medicinal products are subject to good pharmacovigilance practices. These practices include the collection, analysis, and reporting of adverse drug reactions and safety data.

Reporting Requirements: Non-interventional studies may have reporting requirements (e.g., EU PAS Register) to ensure transparency and accountability. This may include the submission of study protocols, study results, safety updates, or other relevant data to regulatory authorities or ethics committees.

It’s important to note that the specific regulations and requirements for non-interventional studies can vary between countries and regions. Researchers conducting non-interventional studies should be familiar with the applicable regulations in their jurisdiction and seek guidance from regulatory authorities, ethics committees, or relevant professional organizations to ensure compliance with the required standards.

Share this story...

Real World Evidence (RWE) 101 – Are Non-Interventional Studies Regulated?2023-08-07T13:12:49+00:00

RWE 101 – The Evolution of Real World Evidence Regulations

RWE 101 – The Evolution of Real World Evidence Regulations

Real-world evidence (RWE) has become an increasingly important source of data for regulatory decision-making in healthcare. The evolution of RWE regulations can be traced back to the late 1990s, when the US Food and Drug Administration (FDA) began to encourage the use of observational studies, such as registries and natural history studies, to supplement clinical trial data in the evaluation of medical products.

In 2011, the FDA launched the Sentinel Initiative, a program that uses electronic health records and other healthcare data sources to monitor the safety of medical products in real time. This initiative paved the way for the use of RWE in regulatory decision-making, and led to the development of guidelines and frameworks for the use of RWE in drug development and regulatory decision-making.

In 2016, the 21st Century Cures Act was signed into law in the US, which included provisions to support the use of RWE in regulatory decision-making. The Act directed the FDA to establish a program to evaluate the potential use of RWE to support drug approvals, and to issue guidance on the use of RWE in regulatory decision-making.

In 2018, the FDA issued its first guidance on the use of RWE to support drug approvals, which outlined the types of RWE that could be used, the study designs that could be employed, and the factors that would be considered in the evaluation of RWE. The guidance also emphasized the importance of ensuring the quality and reliability of RWE, and the need for transparent reporting and validation of RWE studies.

Since then, regulatory agencies around the world have continued to develop guidelines and frameworks for the use of RWE in regulatory decision-making. For example, the European Medicines Agency (EMA) has established a framework for the use of RWE in the evaluation of medicines, which includes the use of RWE to support marketing authorizations and post-authorization safety monitoring.

Overall, the evolution of RWE regulations reflects the growing recognition of the value of real-world data in healthcare decision-making, and the need for guidelines and frameworks to ensure the quality and reliability of RWE studies.

Share this story...

RWE 101 – The Evolution of Real World Evidence Regulations2023-08-07T22:41:24+00:00

China | CMD Publishes 2022 China NMPA (CFDA) Blue Book: Revised Medical Device and IVD Regulation

Please login to view this page.

China | CMD Publishes 2022 China NMPA (CFDA) Blue Book: Revised Medical Device and IVD Regulation2022-08-07T16:44:24+00:00
Go to Top